Evolus sells Jeuveau and Evolysse injectable aesthetic treatments to licensed aesthetic practitioners. EOLS reports earnings on Wed, Nov 4, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 25 | HC Wainwright & Co. | Reiterated | Buy | |
| Jun 17 | BTIG | Reiterated | Buy |
Seasonality
How EOLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in EOLS in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EOLS is in one of them and how their past EOLS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EOLS in an article yet. Here's the latest on the wider market.
About Evolus
Evolus is a medical aesthetics company based in Newport Beach, California. It sells Jeuveau, an injectable botulinum toxin used to smooth frown lines, and Evolysse, a line of injectable hyaluronic acid gels used for wrinkles, folds, and facial volume. Its customers are licensed aesthetic practitioners, and patients generally pay for these treatments directly out of pocket rather than through insurance. The company relies on outside manufacturers in South Korea and France to produce its products.
- Headquarters
- Newport Beach, CA